Together, since MEG3 potentially regulates multiple downstream pathways, Rb mediated induction of MEG3 may not only be important in the treatment of NSCLC and breast cancer, but in other cancer types that are responsive to palbociclib, and further studies are needed to determine the potential benefit of combinatorial therapies against these cancers. This evidence concerns the gene MEG3 and non-small cell lung carcinoma.